Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506.

Authors :: Carbajo-Lozoya J
Müller MA
Kallies S
Thiel V
Drosten C
von Brunn A
Source :: Virus research [Virus Res] 2012 Apr; Vol. 165 (1), pp. 112-7. Date of Electronic Publication: 2012 Feb 10.
Publication Year :: 2012
Abstract: Recent research has shown that Coronavirus (CoV) replication depends on active immunophilin pathways. Here we demonstrate that the drug FK506 (Tacrolimus) inhibited strongly the growth of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E at low, non-cytotoxic concentrations in cell culture. As shown by plaque titration, qPCR, Luciferase- and green fluorescent protein (GFP) reporter gene expression, replication was diminished by several orders of magnitude. Knockdown of the cellular FK506-binding proteins FKBP1A and FKBP1B in CaCo2 cells prevented replication of HCoV-NL63, suggesting the requirement of these members of the immunophilin family for virus growth.<br /> (Copyright © 2012 Elsevier B.V. All rights reserved.)

Subjects :: Caco-2 Cells
Coronavirus 229E, Human physiology
Coronavirus Infections genetics
Coronavirus Infections metabolism
Coronavirus Infections virology
Coronavirus NL63, Human physiology
Humans
Severe acute respiratory syndrome-related coronavirus physiology
Severe Acute Respiratory Syndrome genetics
Severe Acute Respiratory Syndrome metabolism
Severe Acute Respiratory Syndrome virology
Tacrolimus Binding Proteins genetics
Tacrolimus Binding Proteins metabolism
Coronavirus 229E, Human drug effects
Coronavirus NL63, Human drug effects
Severe acute respiratory syndrome-related coronavirus drug effects
Tacrolimus pharmacology
Virus Replication drug effects

Full Text Access

Tools